Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972854 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
A Phase 3 study, sponsored by Glaukos Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
NCT01972854: Clinical Trial Phase 3 study, sponsored by Glaukos Corporation.
NCT01972854 is a Phase 3 study that was terminated before completion, run by Glaukos Corporation. The registered enrollment target is 92 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01972854, a Phase 3 study, was terminated before completion, sponsored by Glaukos Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.
Primary Outcome
The primary endpoint is the mean change from baseline to 12 months in maximum corneal curvature (Kmax) between the VibeX treatment group and the Placebo control group.
Interventions
- DRUG riboflavin solution
- DRUG placebo solution
- DEVICE KXL System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 3 |
Why NCT01972854 stopped before completion
NCT01972854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which riboflavin solution is the first listed.
NCT01972854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01972854 about?
NCT01972854 is a clinical study titled "Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus". The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.
What is the current status of trial NCT01972854?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2013-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01972854?
The interventions under investigation include: riboflavin solution (DRUG), placebo solution (DRUG), KXL System (DEVICE).
Who is sponsoring clinical trial NCT01972854?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01972854's enrollment target sits among peer trials
92 1723rd of 2000 higher than 277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia